Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia

Rasim Gucalp, Paul Ritch, Peter H. Wiernik, P. Ravi Sarma, Alan Keller, Stephen P. Richman, Kurt Tauer, James Neidhart, Lawrence E. Mallette, Robert Siegel, Christine J. VandePol

Research output: Contribution to journalArticlepeer-review

149 Scopus citations


Purpose: This multicenter, double-blind, randomized trial was performed to determine the efficacy and safety of pamidronate disodium (APD) in comparison to etidronate disodium (EHDP) in the treatment of Cancer-related hypercalcemie. Patients and Methods: Sixty-five male and female adult patients with Cancer and corrected calcium levels of ≥ 12.0 mg/dL after 24 hours of hydration were randomized to receive either 60 mg APD given as a single 24-hour infusion or 7.5 mg/kg EHDP given as a 2-hour infusion daily for 3 days. Results: APD normalized corrected calcium levels in 70% (21 of 30) of patients, whereas EHDP did so in 41% (14 of 34) of patients (P = .026). The mean corrected serum calcium level decreased from 14.6 to 10.5 mg/dL in the APD-treerted group and from 13.8 to 11.6 mg/dL in the EHDP-treated group within the first week of treatment. There was no difference in response to APD in patients without versus those with bone metastases (78% v 67%). Both drugs were well tolerated. Conclusion: This study demonstrated that a single 60-mg infusion of APD is safe and more effective than EHDP given at the dose of 7.5 mg/kg for 3 days in the treatment of Cancer-related hypercalcemia.

Original languageEnglish (US)
Pages (from-to)134-142
Number of pages9
JournalJournal of Clinical Oncology
Issue number1
StatePublished - 1992

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia'. Together they form a unique fingerprint.

Cite this